Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
ConditionAndrogenetic Alopecia (AGA)
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorShanghai Zhongshan Hospital
About this trial
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:
• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.
Participants will:
* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinically diagnosed with androgenetic alopecia (AGA)
No pregnancy plans within the next 6 months
Disqualifiers
Patients who received systemic medications for hair loss within the past 2 months
Use of topical medication for hair loss within the past 2 weeks
Pregnancy or lactation
Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Trial design
Design model
Parallel
Treatments tested in this trial
Oral DHA + Topical minoxidil 5%
DrugDHA 20mg tid po plus daily topical minoxidil 5% for 180 days
Topical Minoxidil 5%
DrugTopical minoxidil 5% daily for 180 days
Treatment groups
30 Participants
are divided into 2 treatment groupsGroup A: Intervention ArmActive comparator 1 intervention
Group B: Control ArmOther 1 intervention
Trial outcomes
Primary outcomes
1
Improvement in terminal hair follicles in the vertex area
Terminal hair follicles in the vertex area will be quantified before and at the end of treatment
Time frame
Baseline and 180-day of treatmentSecondary outcomes
1
Change of terminal hair follicle density in the vertex area from baseline to the end of treatment
Time frame
Baseline and 180-day of treatment2
Change of hair density in the vertex area from baseline to the end of treatment
Time frame
Baseline and 180-day of treatment3
Change of terminal hair follicle density in the frontal area from baseline to the end of treatment
Terminal hair follicle density in the frontal area
Time frame
Baseline and 180-day of treatment4
Change of hair density in the frontal area from baseline to the end of treatment
Time frame
Baseline and 180-day of treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov